HIV testing and prevention is funded by local government through the ringfenced Public Health Grant. We have provided £3.324 billion to local authorities in England to fund public health services in 2021/22, including sexual health and HIV services. We have invested in the successful deployment of pre-exposure prophylaxis (PrEP) in England and the Public Health Grant in 2021/22 includes £23.4 million to cover local authorities\u2019 costs of routine commissioning of PrEP.<\/p>
Funding for HIV treatment and care services is provided by NHS England and NHS Improvement through specialised commissioning. Decisions on future funding for are being taken as part of the forthcoming Spending Review. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for HIV prevention services Funding for PrEP in 2021/22 has been allocated using a specific formula which recognises that the level of risk of acquiring HIV is distributed differently to the approach taken for the Public Health Grant.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"} } , "answeringMemberConstituency" : {"_value" : "Erewash"} , "answeringMemberPrinted" : {"_value" : "Maggie Throup"} , "dateOfAnswer" : {"_value" : "2021-10-25", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "56275"} , {"_value" : "56294"} , {"_value" : "56420"} , {"_value" : "57387"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-10-25T16:53:44.39Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-10-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "HIV Infection: Disease Control"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what funding is being made available to help eradicate HIV transmission in England by 2030.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4777", "label" : {"_value" : "Biography information for Sarah Owen"} } , "tablingMemberConstituency" : {"_value" : "Luton North"} , "tablingMemberPrinted" : [{"_value" : "Sarah Owen"} ], "uin" : "57386"} , {"_about" : "http://data.parliament.uk/resources/1202047", "AnsweringBody" : [{"_value" : "Department for International Development"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1202047/answer", "answerText" : {"_value" : "
The UK announced our new pledge of £160 million in humanitarian funding for Yemen in the 2020/21 financial year at the Yemen Pledging Conference on 2 June.<\/p>
As part of this commitment, the UK will support the UN\u2019s plans to tackle the spread of COVID-19 in Yemen and expects to provide over 700,000 medical consultations, train 12,000 healthcare workers to work safely in a COVID-19 environment and provide a much-needed boost to nearly 4,000 health centres to continue providing existing health services.<\/p>
In addition, the UK is also supporting the Yemeni Private Sector Cluster, which in April sourced a vital shipment of COVID-19 related supplies and equipment for Yemen.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4366", "label" : {"_value" : "Biography information for James Cleverly"} } , "answeringMemberConstituency" : {"_value" : "Braintree"} , "answeringMemberPrinted" : {"_value" : "James Cleverly"} , "dateOfAnswer" : {"_value" : "2020-06-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "57387"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-06-15T15:30:34.207Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2020-06-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Yemen: Coronavirus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for International Development, what steps he is taking to ensure that some of the Government\u2019s £160 million humanitarian aid package for Yemen is used to stop the spread of covid-19 in communities on both sides of the conflict; and what assessment he has made of the potential merits of using UN-backed Yemeni-led frameworks established by (a) the International Initiative on COVID-19 in Yemen and (b) other private sector organisations to deliver aid to both sides.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4772", "label" : {"_value" : "Biography information for Kenny MacAskill"} } , "tablingMemberConstituency" : {"_value" : "East Lothian"} , "tablingMemberPrinted" : [{"_value" : "Kenny MacAskill"} ], "uin" : "57386"} , {"_about" : "http://data.parliament.uk/resources/657931", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/657931/answer", "answerText" : {"_value" : "
We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) has advised that the proposed arrangements are intended to provide clarity about the level of cost effectiveness below which funding will be made available, automatically and without delay, for highly specialised technologies that receive positive recommendations from NICE.<\/p>
<\/p>
Subject to the outcome of the current consultation exercise, those products that have a value proposition of above £100,000 per quality-adjusted life year will be provided with a further opportunity to be considered for use in the National Health Service, through NHS England\u2019s annual process for deciding which new treatments and services will be routinely commissioned.<\/p>
<\/p>
Furthermore, the proposed changes are intended to clarify NICE\u2019s existing responsibility to determine the period within which funding for recommended products needs to be made available by commissioners of services. This clarity should allow companies and commissioners to work on commercial arrangements in advance of and in parallel with the development of NICE technology appraisal and highly specialised technology guidance. In circumstances where this may not be possible, specific requests from commissioners to vary the timescale for the funding requirement will be considered by NICE.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"} , "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"} , "dateOfAnswer" : {"_value" : "2016-12-20", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "57384"} , {"_value" : "57385"} , {"_value" : "57387"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-12-20T15:55:01.62Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-12-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the potential effect of the £100,000 quality adjusted life year threshold for evaluating Highly Specialised Technologies on the access and update of new medicines for patients with very rare and complex diseases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"} } , "tablingMemberConstituency" : {"_value" : "Cambridge"} , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"} ], "uin" : "57386"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }